General Information and Variability Data of DT
DT ID DTD0019
Gene Name SLC10A1
Protein Name Sodium/taurocholate cotransporting polypeptide
Synonyms Cell growth-inhibiting gene 29 protein; NTCP; Na(+)/bile acid cotransporter; Na(+)/taurocholate transport protein; SLC10A1; Sodium/bile acid cotransporter; Solute carrier family 10 member 1
Gene ID
6554
UniProt ID
Q14973
TCDB ID
2.A.28.1.9
DT Family Bile Acid:Na(+) Symporter (BASS) Family ;
Function This tranporter strictly dependent on the extracellular presence of sodium and exhibits broad substrate specificity and transports various non-bile acid organic compounds as well.
Disease(s) Hypercholesterolemia [ICD-11: 5C80.0]
Hypothyroidism [ICD-11: 5A00.2]
Hyperlipidaemia [ICD-11: 5C8Z]
Genetic Polymorphisms & Epigenetic Regulations of DT
Species-, Tissue- and Disease-specific Protein Abundances of DT
Exogenous Factor Altering DT Activity
Approved Drug(s) Transported by This DT Cerivastatin Drug Info Hyperlipidaemia [ICD-11: 5C8Z] Approved [1]
Estrone sulfate Drug Info Menopausal symptoms [ICD-11: MF32] Approved [2]
Liothyronine Drug Info Hypothyroidism [ICD-11: 5A00.2] Approved [3]
Pitavastatin calcium Drug Info Dyslipidaemias [ICD-11: 5C8Z] Approved [4]
Rosuvastatin Drug Info Hypercholesterolemia [ICD-11: 5C80.0] Approved [5]
Withdrawn, Discontinued or Preclinical Drug(s) Transported by This DT Sodium taurocholate Drug Info Type 2 diabetes [ICD-11: 5A11] Preclinical [6]
Taurocholic acid Drug Info Type 2 diabetes [ICD-11: 5A11] Terminated [7]
Endogenous Substrate(s) Bile acids; Bile conjugates; Steroids; Cholate; Tauroursodeoxycholate
Endogenous Metabolites (EMs) Handled by This DT Bile acid unspecific EM Info Identified using mouse NASH model [8]
Drug-DT Affinity Assessed by Cell Line
Drug(s) with Drug-DT Affinity Data Estrone sulfate Drug Info Human cervical cancer cell line (Hela)-NTCP Km = 27 microM [2]
Pitavastatin calcium Drug Info Oocytes-NTCP Km = 15.1 microM [4]
Rosuvastatin Drug Info Human cervical cancer cell line (Hela)-NTCP Km = 65 microM [5]
Sodium taurocholate Drug Info Human cervical cancer cell line (Hela)-NTCP Km = 7.5 microM [2]
Sodium taurocholate Drug Info Human cervical cancer cell line (Hela)-NTCP Km = 7.9 microM [7]
Sodium taurocholate Drug Info Human embryonic kidney cells (HEK293)-NTCP Km = 2.1 microM [6]
Taurocholic acid Drug Info Human cervical cancer cell line (Hela)-NTCP Km = 7.9 microM [7]
Taurocholic acid Drug Info Oocytes-NTCP Km = 6.2 microM [9]
References
1 Differential effect of genetic variants of Na(+)-taurocholate co-transporting polypeptide (NTCP) and organic anion-transporting polypeptide 1B1 (OATP1B1) on the uptake of HMG-CoA reductase inhibitors. Xenobiotica. 2011 Jan;41(1):24-34.
2 Ethnicity-dependent polymorphism in Na+-taurocholate cotransporting polypeptide (SLC10A1) reveals a domain critical for bile acid substrate recognition. J Biol Chem. 2004 Feb 20;279(8):7213-22.
3 Identification of thyroid hormone transporters. Biochem Biophys Res Commun. 1999 Jan 19;254(2):497-501.
4 Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol. 2005 Oct;57(10):1305-11.
5 Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology. 2006 May;130(6):1793-806.
6 Differential inhibition of rat and human Na+-dependent taurocholate cotransporting polypeptide (NTCP/SLC10A1)by bosentan: a mechanism for species differences in hepatotoxicity. J Pharmacol Exp Ther. 2007 Jun;321(3):1170-8.
7 Modulation by drugs of human hepatic sodium-dependent bile acid transporter (sodium taurocholate cotransporting polypeptide) activity. J Pharmacol Exp Ther. 1999 Dec;291(3):1204-9.
8 Disruption of phospholipid and bile acid homeostasis in mice with nonalcoholic steatohepatitis. Hepatology. 2012 Jul;56(1):118-29.
9 Molecular cloning, chromosomal localization, and functional characterization of a human liver Na+/bile acid cotransporter. J Clin Invest. 1994 Mar;93(3):1326-31.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.